Undisclosed liver-expressed gene mRNA

Undisclosed liver-expressed gene mRNA is a placeholder designation used by biotechnology and pharmaceutical companies to identify a proprietary therapeutic target while maintaining intellectual property confidentiality. This terminology is commonly found in the early-stage pipelines of companies specializing in RNA-targeted modalities, such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals (Alnylam, 2024; Arrowhead, 2024). The target refers to a specific messenger RNA (mRNA) sequence that encodes a protein involved in the pathogenesis of a disease, typically within the context of metabolic, cardiovascular, or rare genetic conditions. Therapeutic intervention usually involves the use of small interfering RNA (siRNA) or antisense oligonucleotides (ASOs) designed to bind to the mRNA and trigger its degradation or inhibit its translation. By silencing the gene at the transcript level, these drugs reduce the production of the disease-associated protein. The liver is a frequent focus for such undisclosed targets because it is highly accessible to advanced delivery technologies like GalNAc-conjugation and lipid nanoparticles. The specific identity and biological role of the gene are typically revealed only after the drug candidate reaches significant clinical or regulatory milestones.

Other names

Undisclosed hepatic targetProprietary liver mRNA targetUndisclosed liver gene

RNA interference (RNAi) or antisense-mediated gene silencing